Enhanced White Light Endoscopy Versus Conventional White Light Endoscopy for Colorectal Adenoma Detection: A Randomized Controlled Trial

NCT ID: NCT06979232

Last Updated: 2025-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-20

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Study on Adenoma Detection Rate (ADR) Comparing Enhanced White Light Endoscopy (E-WLI) versus Conventional White Light Endoscopy (WLI);
2. Study Comparing Enhanced White Light Endoscopy (E-WLI) versus Conventional White Light Endoscopy (WLI) for Detection Rates of Sessile Serrated Lesions (SSLs), Total Polyp Detection Rate, and Advanced Adenoma Detection Rate;
3. Study on Polyp Characteristics (Size, Location, etc.) Observed Using Conventional White Light Endoscopy (WLI) and Enhanced White Light Endoscopy (E-WLI).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Before colonoscopy, gastroenterology specialists stratified eligible patients according to 1) colorectal cancer screening, 2) positive fecal immunochemical test (FIT) results or gastrointestinal symptoms, and 3) follow-up colonoscopy after colorectal polyp treatment. Patients were then randomized in a 1:1 ratio to receive either colonoscopy with enhanced white light imaging (E-WLI group) or high-definition conventional white light imaging (WLI group) during both insertion and withdrawal phases. Randomization was based on random number lists generated by the coordinating center for each participating site. Endoscopists performing the procedures were not involved in generating the randomization sequence. All procedures were performed by experienced endoscopists at participating centers (\>2000 colonoscopy screenings). All procedures utilized endoscopes with "Xiaohua Tanying" technology that incorporated E-WLI functionality. Bowel preparation was assessed and graded by the performing endoscopist using the Boston Bowel Preparation Scale (BBPS). Endoscopy specialists and healthcare facility staff followed standard procedures for patient management and monitoring, including anesthesia. Cecal intubation was verified by the endoscopist through photographic documentation identifying the ileocecal valve and appendiceal orifice. Insertion and withdrawal times were measured through video recording analysis, excluding time spent on therapeutic interventions and washing. Endoscopists were required to maintain a minimum withdrawal inspection time of 6 minutes (with at least 2 minutes each for right colon, transverse colon, and left colon). Regardless of group assignment (E-WLI or WLI), when polyps were detected during the procedure, they were observed using both WLI and E-WLI (2 modes), with images captured in each mode. The location, size, and morphology (Paris classification) of all polyps were documented. All polyps were removed (or biopsied if unresectable), and pathological results were obtained. For hyperplastic polyps in the rectum, if more than 3 diminutive polyps were present, only the first 3 detected polyps required management.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Adenoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

E-WLI

Enhanced White Light Imaging

Group Type EXPERIMENTAL

Enhanced White Light Imaging

Intervention Type DEVICE

Use of E-WLI for colon inspection during both insertion and withdrawal phase of colonoscopy

WLI

White Light lmaging

Group Type PLACEBO_COMPARATOR

White Light lmaging

Intervention Type DEVICE

Use of WLl for colon inspection during both insertion and withdrawal phase of colonoscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enhanced White Light Imaging

Use of E-WLI for colon inspection during both insertion and withdrawal phase of colonoscopy

Intervention Type DEVICE

White Light lmaging

Use of WLl for colon inspection during both insertion and withdrawal phase of colonoscopy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Male or female aged 45 to 85
* 2\. Patients undergoing colonoscopy for colorectal cancer screening, positive fecal immunochemical test (FIT) results, gastrointestinal symptoms, or follow-up examination after colorectal polyp treatment
* 3\. Capable of providing informed consent and agreeing to participate
* 4\. Able and willing to follow all research processes

Exclusion Criteria

* 1\. Participated in other clinical trials, signed informed consent form, and in the follow-up period of other clinical trials;
* 2\. Participated in clinical trials of drugs and is in the discontinuation period of experimental or control drugs;
* 3\. Have had drug or alcohol abuse or psychological disorders in the past five years.
* 4\. Pregnant or lactating patients;
* 5\. Known to have polyposis syndrome;
* 6\. Patients with gastrointestinal bleeding;
* 7\. Previous history of inflammatory bowel disease, colorectal cancer, or colorectal surgery;
* 8.Patients with contraindications to tissue biopsy;
* 9\. History of allergies to the ingredients in intestinal cleansers;
* 10\. Individuals with conditions such as intestinal obstruction or perforation, toxic megacolon, heart failure (grade III or IV), severe cardiovascular disease, severe liver failure, or renal insufficiency, among others.
* 11\. Researchers believe that patients are not suitable to participate in the trial.
Minimum Eligible Age

45 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xiaobo Li

Chief physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chongqing General Hospital

Chongqing, Chongqing Municipality, China

Site Status ACTIVE_NOT_RECRUITING

The First People's Hospital of Lanzhou City

Lanzhou, Gansu, China

Site Status RECRUITING

The Third Affiliated Hospital of Heilongjiang University of Chinese Medicine

Harbin, Heilongjiang, China

Site Status NOT_YET_RECRUITING

Armed Police Forces Hospital of Sichuan

Leshan, Sichuan, China

Site Status RECRUITING

People's Hospital of Bayingolin Mongol Autonomous Prefecture

Korla, Xinjiang, China

Site Status NOT_YET_RECRUITING

Ningbo Ninth Hospital

Ningbo, Zhejiang, China

Site Status RECRUITING

Taizhou First People's Hospital

Taizhou, Zhejiang, China

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Qing-Wei Zhang, MD

Role: CONTACT

021-68383015

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Weichun Zhai

Role: primary

15095321372

Zhe Wang

Role: primary

15804514492

Ruilan Wang

Role: primary

13881368101

Hongli Tian

Role: primary

18099966639

Jian Huang

Role: primary

13819448881

Xinyuan Shi

Role: primary

15157628698

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LY2024-320-C

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.